Livagen 20mg Nasal Spray

Description

This livagen nasal spray supplies Livagen, a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Ala, abbreviated KEDA. It comes from the short peptide bioregulator programme at the St Petersburg Institute of Bioregulation and Gerontology, and within that framework it is associated with hepatic tissue. Most compounds in this class rest entirely on a gene-regulation hypothesis. Livagen is the exception, because it has one published activity that was measured directly with a number attached. Supplied for laboratory research use only.

The one hard number in this compound class

Enkephalins are endogenous opioid peptides, and they are broken down by a group of serum enzymes usually called enkephalin-degrading enzymes or enkephalinases. Inhibit those enzymes and enkephalins persist longer. This is straightforward enzymology, measurable in a tube, with no hypothesis required.

A study indexed at PMID 12942748 examined the effect of Livagen and Epitalon on enkephalin-degrading enzymes from human serum, assaying activity by the rate of tritiated Leu-enkephalin hydrolysis in the presence of each peptide. The reported IC50 for Livagen was 20 micromolar, and the report describes it as more efficient than established peptidase inhibitors including puromycin, leupeptin and D-PAM.

Two things make this worth leading with. It is falsifiable in a way the DNA-binding hypothesis is not: any competent laboratory with a peptidase assay can attempt to reproduce an IC50, and either the number holds or it does not. And it gives you a positive control for your own material. If you are working with Livagen and want to know whether the peptide in your vial is behaving as described in the literature, an enkephalinase inhibition assay is a concrete functional check rather than a purity certificate.

The caveats are equally worth stating. Twenty micromolar is a modest potency, well above the nanomolar range where high-affinity ligands operate, so this is a weak inhibitor rather than a pharmacological tool compound. The work originates from the same research lineage as the rest of the series. And enkephalinase inhibition is not obviously connected to hepatic tissue specificity, so it does not validate the broader bioregulator model. It is one real measurement, not a mechanism.

How Livagen differs from Ovagen

Both are hepatic-associated peptides from the same programme, and confusing them is easy. Ovagen is Glu-Asp-Leu, a tripeptide. Livagen is Lys-Glu-Asp-Ala, a tetrapeptide. Different length, different composition, different net charge: Ovagen carries two acidic residues and no basic one, while Livagen carries a lysine alongside its acidic residues, which changes its charge profile and its chromatographic behaviour.

For a methods section, name the sequence rather than the trade name, because “liver bioregulator” describes at least two distinct molecules in this catalogue and reviewers will not guess which you used.

The shared mechanism claim, and its limits

The proposal across this series is that short peptides enter cells, reach the nucleus and interact with DNA promoter regions or chromatin-associated histones, changing which genes are accessible to transcription factors. Supporting work includes mobility shift assays showing peptide-DNA complexes, histone binding assays and molecular docking models, argued in Short Peptides Regulate Gene Expression in the Bulletin of Experimental Biology and Medicine.

The limits are the same as for the rest of the class. The evidence is preclinical and concentrated within one research lineage, independent replication outside it is limited, high-resolution structural confirmation of a peptide-DNA complex is unpublished, and there are no human clinical trials or regulatory approvals. Treat the model as a hypothesis to test rather than a description of established fact.

Livagen nasal spray specifications

In-vitro considerations for intranasal livagen research

For hepatic work the usual models are HepG2, HepaRG or primary human hepatocytes, and the choice matters more than people allow. HepG2 is convenient and immortalized but expresses drug-metabolising enzymes at far lower levels than real hepatocytes, so it is a poor model for anything touching hepatic metabolic competence. HepaRG differentiates toward a more hepatocyte-like phenotype. Primary hepatocytes are closest to the tissue and dedifferentiate quickly in culture, which puts a clock on the experiment.

Because the proposed mechanism is transcriptional, qPCR or RNA-seq belongs in the readout panel, with protein-level confirmation of any transcript hit. And the enkephalinase result above suggests an entirely different and simpler experiment: a cell-free peptidase assay, which requires no assumptions about membrane permeability at all. If you want a first experiment with this compound that can actually fail, that is the one I would run.

Livagen nasal spray storage and handling

KEDA contains no cysteine, no methionine and no tryptophan, so disulfide chemistry, oxidation and photodegradation are not the practical risks here. Charge and enzymatic exposure are.

With a lysine and two acidic residues, solubility and charge state shift with pH, so buffer control matters more than it appears to. A four-residue peptide is also a ready substrate for serum peptidases, meaning long incubations in serum-containing medium give a declining exposure rather than a fixed one. Sensible livagen nasal spray storage is otherwise routine: cold, sealed, out of light, single-use aliquots rather than repeated freeze-thaw, and low-binding plasticware at low working concentrations.

How research grade livagen spray is characterized

Short, charged peptides retain poorly on standard reversed-phase columns, so the analytical method behind a purity figure is more informative than the figure itself. For a molecule carrying both basic and acidic residues, hydrophilic interaction chromatography, ion-pairing or ion exchange paired with mass spectrometry is appropriate, and a certificate that states its method is worth more than a bare percentage from an unstated one. A research grade livagen spray is supplied under the same verification PrymaLab applies across its research peptides, HPLC and MS confirmation plus independent third-party testing. No specific lot figures are asserted here; request the certificate of analysis for the lot you receive.

For related bioregulator research, see the PrymaLab Research Library.

Frequently asked questions

What is Livagen?

Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala (KEDA), one of the Khavinson-class short peptide bioregulators, associated with hepatic tissue in that framework. Material supplied here is a research chemical for in-vitro laboratory use only.

What is the enkephalinase result?

A published study assayed enkephalin-degrading enzymes from human serum by the rate of tritiated Leu-enkephalin hydrolysis and reported an IC50 of 20 micromolar for Livagen, describing it as more efficient than puromycin, leupeptin and D-PAM. It is a modest potency but a directly measured, reproducible-in-principle result.

How does Livagen differ from Ovagen?

Ovagen is Glu-Asp-Leu, a tripeptide with two acidic residues and no basic one. Livagen is Lys-Glu-Asp-Ala, a tetrapeptide carrying a lysine. Both are hepatic-associated in the Khavinson framework, but they are different molecules with different charge and chromatographic behaviour.

Which liver cell model suits Livagen research?

It depends on the question. HepG2 is convenient but low in drug-metabolising enzyme expression. HepaRG differentiates toward a more hepatocyte-like phenotype. Primary human hepatocytes are closest to tissue but dedifferentiate quickly, which limits experiment duration.

Is Livagen nasal spray approved for human use?

No. This material is a research chemical for in-vitro laboratory use only, has no FDA or EMA approval, and is not intended for human or veterinary use. Nothing here is medical advice.

Ordering and compliance

Every PrymaLab research compound ships from the United States and is sold research-use-only. This livagen nasal spray is supplied for in-vitro laboratory research, is not intended for human or veterinary use, is not a drug or supplement, and has not been evaluated by the FDA for the research-chemical context. Verify the legal status of any research compound in your jurisdiction before ordering. Certificates of analysis are available on request for the lot you receive. [CONFIRM: shipping timeframe and returns policy wording.]